172 related articles for article (PubMed ID: 34861037)
1. Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy.
Yoshikawa T; Wu Z; Inoue S; Kasuya H; Matsushita H; Takahashi Y; Kuroda H; Hosoda W; Suzuki S; Kagoya Y
Blood; 2022 Apr; 139(14):2156-2172. PubMed ID: 34861037
[TBL] [Abstract][Full Text] [Related]
2. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion.
Jung IY; Narayan V; McDonald S; Rech AJ; Bartoszek R; Hong G; Davis MM; Xu J; Boesteanu AC; Barber-Rotenberg JS; Plesa G; Lacey SF; Jadlowsky JK; Siegel DL; Hammill DM; Cho-Park PF; Berger SL; Haas NB; Fraietta JA
Sci Transl Med; 2022 Nov; 14(670):eabn7336. PubMed ID: 36350986
[TBL] [Abstract][Full Text] [Related]
3. Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy.
Ito Y; Inoue S; Kagoya Y
Inflamm Regen; 2024 Mar; 44(1):13. PubMed ID: 38468282
[TBL] [Abstract][Full Text] [Related]
4. Exploring the putative role of PRDM1 and PRDM2 transcripts as mediators of T lymphocyte activation.
Di Zazzo E; Rienzo M; Casamassimi A; De Rosa C; Medici N; Gazzerro P; Bifulco M; Abbondanza C
J Transl Med; 2023 Mar; 21(1):217. PubMed ID: 36964555
[TBL] [Abstract][Full Text] [Related]
5. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models.
Kagoya Y; Nakatsugawa M; Yamashita Y; Ochi T; Guo T; Anczurowski M; Saso K; Butler MO; Arrowsmith CH; Hirano N
J Clin Invest; 2016 Sep; 126(9):3479-94. PubMed ID: 27548527
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
7. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
8. Gene-knocked out chimeric antigen receptor (CAR) T cells: Tuning up for the next generation cancer immunotherapy.
Mirzaei HR; Pourghadamyari H; Rahmati M; Mohammadi A; Nahand JS; Rezaei A; Mirzaei H; Hadjati J
Cancer Lett; 2018 Jun; 423():95-104. PubMed ID: 29544719
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.
Giuffrida L; Sek K; Henderson MA; Lai J; Chen AXY; Meyran D; Todd KL; Petley EV; Mardiana S; Mølck C; Stewart GD; Solomon BJ; Parish IA; Neeson PJ; Harrison SJ; Kats LM; House IG; Darcy PK; Beavis PA
Nat Commun; 2021 May; 12(1):3236. PubMed ID: 34050151
[TBL] [Abstract][Full Text] [Related]
10. CD58 loss in tumor cells confers functional impairment of CAR T cells.
Yan X; Chen D; Ma X; Wang Y; Guo Y; Wei J; Tong C; Zhu Q; Lu Y; Yu Y; Wu Z; Han W
Blood Adv; 2022 Nov; 6(22):5844-5856. PubMed ID: 35728062
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.
Klebanoff CA; Crompton JG; Leonardi AJ; Yamamoto TN; Chandran SS; Eil RL; Sukumar M; Vodnala SK; Hu J; Ji Y; Clever D; Black MA; Gurusamy D; Kruhlak MJ; Jin P; Stroncek DF; Gattinoni L; Feldman SA; Restifo NP
JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212954
[TBL] [Abstract][Full Text] [Related]
12. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
13. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
[TBL] [Abstract][Full Text] [Related]
14. PRDM1 silences stem cell-related genes and inhibits proliferation of human colon tumor organoids.
Liu C; Banister CE; Weige CC; Altomare D; Richardson JH; Contreras CM; Buckhaults PJ
Proc Natl Acad Sci U S A; 2018 May; 115(22):E5066-E5075. PubMed ID: 29760071
[TBL] [Abstract][Full Text] [Related]
15. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
[TBL] [Abstract][Full Text] [Related]
16. New insights into Blimp-1 in T lymphocytes: a divergent regulator of cell destiny and effector function.
Fu SH; Yeh LT; Chu CC; Yen BL; Sytwu HK
J Biomed Sci; 2017 Jul; 24(1):49. PubMed ID: 28732506
[TBL] [Abstract][Full Text] [Related]
17. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.
Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N
J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells.
Jung IY; Kim YY; Yu HS; Lee M; Kim S; Lee J
Cancer Res; 2018 Aug; 78(16):4692-4703. PubMed ID: 29967261
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
20. Transient stimulation expands superior antitumor T cells for adoptive therapy.
Kagoya Y; Nakatsugawa M; Ochi T; Cen Y; Guo T; Anczurowski M; Saso K; Butler MO; Hirano N
JCI Insight; 2017 Jan; 2(2):e89580. PubMed ID: 28138559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
